Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 5, 2013, Pages 366-369

  Pérez Rubio, Karina G ^a   González Ortiz, Manuel ^a,b   Martínez Abundis, Esperanza ^a   Robles Cervantes, José A ^b   Espinel Bermúdez, María C ^b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AREA UNDER CURVE; BERBERINE; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 84884547491     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0183     Document Type: Article

References (17)

1. González-Ortiz M, Martínez-Abundis E, Jacques-Camarena O, et al. Prevalence of MetS in adults with excess of adiposity: Comparison of the Adult Treatment Panel III criteria with the International Diabetes Federation definition. Acta Diabetol 2006;43:84-86.
2. Poirier P, Després JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 2003;23:161-169.
3. van Harmelen V, Dicker A, Rydén M, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002;51:2029-2036.
4. Robles-Cervantes JA, Martínez-Abundis E, González-Ortiz M, et al. Behavior of insulin sensitivity and its relation to leptin and tumor necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up. Obes Surg 2007; 17:1242-1247.
5. Derosa G, Maffioi P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12: 1113-1124.
6. Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat stores and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med 2012, 2012: Doi:10.1155/2012/363845.
7. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 1st International Congress on Prediabetes and the Metabolic Syndrome: Epidemiology, management and prevention of diabetes and cardiovascular disease, April 24, 2009, Berlin, Germany. 8. Stumvoll M, Mitrakou A, Pimienta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301.
8. MatsudaM,DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470.
9. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian Pediatr 1989;26:115-121.
10. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;26:77-83.
11. Derosa G, Maffioli P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12: 1113-1124.
12. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-717.
13. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-2565.
14. Liu L, Yu YL, Yang JS, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 2010;381:371-381.
15. Zhou JY, Zhou SW, Zhang KB, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 2008;31:1169-1176.
16. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-1351.
17. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007;57:26-30.